AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05465629 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: VIOME Precision Nutrition Program
Description: Precision supplement based on the participants microbiome sample results. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
Study NCT05465629 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VIOME-designed condition-based supplements
Description: Pre-formulated supplements based on overall health conditions. Participants in this arm may have any combination of supplements, diet recommendations, and/or coaching.
Study NCT05980949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KarXT
Description: KarXT 20/2 mg TID (total daily dose \[TDD\] 60/6 mg) KarXT 30/3 mg TID (TDD 90/9 mg) KarXT 40/4 mg TID (TDD 120/12 mg) KarXT 50/5 mg TID (TDD 150/15 mg) KarXT 66.7/6.67 mg TID (TDD 200/20 mg)
Study NCT05140200 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3511294
Description: GSK3511294 will be administered.
Study NCT06656975 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Therapy
Description: This intervention will be delivered by participants Behavioral Health Care Manager during Collaborative Care Management appointments. These appointments typically take place over video call (telehealth). Each intervention consists of 4 sessions (approximately 20 minutes each), delivered over 3 months. Participants will also receive a one-time introductory session before starting the first intervention. Between sessions, there will be homework tasks, such as filling out worksheets or completing goals that are set with the provider.~The therapy portion of the appointment only will be audio recorded using a voice recorder or secure meeting software. Audio recordings will be reviewed by study staff for training and compliance purposes.
Study NCT06656975 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Prescribing
Description: This intervention will be delivered by participants Behavioral Health Care Manager during Collaborative Care Management appointments. These appointments typically take place over video call (telehealth). Each intervention consists of 4 sessions (approximately 20 minutes each), delivered over 3 months. Participants will also receive a one-time introductory session before starting the first intervention. Between sessions, there will be homework tasks, such as filling out worksheets or completing goals that are set with the provider.~The therapy portion of the appointment only will be audio recorded using a voice recorder or secure meeting software. Audio recordings will be reviewed by study staff for training and compliance purposes.
Study NCT06656975 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Usual Care
Description: Participants will receive an informational booklet on improving loneliness. Participants may initiate or continue Collaborative Care for other conditions on a not research basis.
Study NCT06660394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP352
Description: LP352 will be administered orally or through G-tube/ percutaneous endoscopic gastrostomy (PEG) tube
Study NCT06660394 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered with matching placebo orally or through G-tube/ PEG tube
Study NCT06607276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab and capecitabine
Description: Adebrelimab: 1200mg, IV, q3w for one year; capecitabine:1250mg/m2, po, bid,d1-14, q3w, for 6-8 cycles
Study NCT06607276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: capecitabine:1250mg/m2, po, bid,d1-14, q3w, for 6-8 cycles
Study NCT06395090 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT06395090 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab
Description: IV infusion
Study NCT06395090 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab/Pembrolizumab
Description: IV infusion
Study NCT06395090 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vibostolimab
Description: IV infusion
Study NCT06395090 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Vibostolimab
Description: IV infusion
Study NCT06610838 — intervention group
Intervention type: OTHER
Intervention: Health Assessments
Description: Participants will complete the blood tests, questionnaires, cardiovascular tests, and pulmonary test at visits 1, 2, and 4. Non-Contrast Chest CT and cardiopulmonary treadmill (VO2 max) stress tests will occur at visits 1 and 4. Visit 3 will not include cardiovascular and pulmonary tests.
Study NCT06662344 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: Nasogastric Tube Feeding were used for feeding to provide nutritional support. Each feeding was administered by a nurse using the infant's mother's breast milk through the tube. The amount of each feeding varied from 20 to 100 ml depending on the age of the infant, with feedings given every 2 to 3 hours, approximately 10 times per day. The duration of each feeding procedure ranged from 10 to 20 minutes. The total daily intake ranged from 200 to 1000 ml. Each tube was kept indwelling for 5 to 7 days. When the tube needed to be replaced, it was removed after the last feeding of a day and a new tube was to be inserted through the other nostril on the following morning to continue the nutritional support.
Study NCT05125016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4336
Description: Administered once weekly (QW) by subcutaneous (SC) injection, or intravenous (IV) infusion
Study NCT06411041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training (PFMT) and yoga
Description: The experimental group participants will be instructed to perform the practice session four days a week. The four days per week practice times (PFMT 15 minutes/day; yoga 40 minutes/day.) will result in weekly practice times for pelvic floor muscle training (PFMT) of 60 minutes and for yoga of ≥150 minutes.
Study NCT06151834 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: KeriFuse implant implantation
Description: The surgery is an arthrodesis of finger or thumb (for patients with finger osteoarthritis) and involves implanting the KeriFuse implant.
Study NCT05125016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered concomitantly every 3 weeks (Q3W) by IV infusion
Study NCT05125016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5678
Description: Administered concomitantly QW by IV infusion
Study NCT05125016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Administered once by IV infusion as prophylaxis prior to REGN4336 IV
Study NCT06662344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation therapy
Description: Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study NCT06662344 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive rehabilitation therapy
Description: Both groups were given comprehensive rehabilitation therapy. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study NCT06658392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive tasks
Description: no intervention in a medical sense, only observing changes of BOLD signal during different experimental conditions in cognitive tasks (arithmetic, attention, inhibition)
Study NCT06658769 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Theta Burst Stimulation
Description: Transcranial Magnetic Stimulation (TMS): A non-invasive brain stimulation (NIBS) technique that involves modulating brain excitability and activity, which can increase or decrease depending on the parameters used. Theta Burst Stimulation (TBS) mimics the brain's natural firing patterns more closely and may have greater effects on cognitive performance.
Study NCT06658769 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Theta Burst Stimulation Sham
Description: Theta Burst Stimulation simulated with 90º coil orientation with lower part external to the scalp.
Study NCT05732428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-471
Description: ARV-471 will be administered orally once daily with food (eg, a light meal of approximately 400 to 600 calories which includes a mixture of fat carbohydrates, and protein) at RP3D for monotherapy defined in study ARV-471-mBC-101, in continuous dosing over 28-day cycles
Study NCT05143138 — intervention group
Intervention type: DEVICE
Intervention: GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis
Description: Patients treated with the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis as a Bridging Stent
Study NCT06042049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirsevimab
Description: Participants in the first year of life will receive the 1st dose of nirsevimab as a single, fixed intramuscular (IM) dose of 50 mg if body weight is \<5 kg or 100 mg if body weight is ≥5 kg. A 2nd fixed IM dose of 50 mg if body weight is \<5 kg or 100 mg if body weight is ≥5 kg will be administered 5 to 6 months following the 1st dose.
Study NCT06069843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Ketamine
Description: 0.5 mg/kg IV Ketamine
Study NCT04922333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Description: 150mg over-encapsulated risedronate
Study NCT00256035 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Measuring IL-4 levels
Study NCT06661447 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tridimensional Onlay autologous bone graft
Description: A thick block from the ramus area of the mandible are cut longitudinally with a microsaw into two thin pieces with the same surface area. The two thin block are used to rebuild the two wall of the future alveolar crest and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.
Study NCT06661447 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tridimensional Onlay xenogeneic bone graft
Description: A tridimensional Onlay xenogeneic bone graft is positioned and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.
Study NCT06661447 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tridimensional Onlay allogenic bone graft
Description: A tridimensional Onlay allogenic bone graft is positioned and stabilized with osteosynthesis screw of the edentulous area. The remaining space is filled with a mixture of autogenic and xenogeneic particulate bone.
Study NCT04435639 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual lymph drainage.
Description: Manual Lymphatic drainage:~Patients will receive manual lymphatic drainage by massage for 40 minutes for 5 treatments over a 15 day period.
Study NCT04435639 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual lymph drainage.
Description: Manual Lymphatic drainage:~Patients will receive manual lymphatic drainage by massage for 40 minutes for 5 treatments over a 15 day period.
Study NCT04435639 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coban compression bandage..
Description: Coban compression bandaging: Patients will be wrapped in Coban compression bandaging which stays on until the next treatment. Patients will wear standard compression sleeves during the six month maintenance phase.
Study NCT04435639 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable Compression Sleeve
Description: Patients wear an adjustable compression sleeve (Juzo varocare adjustable compression system) between treatments. They will be shown how to put it on and how to tighten the sleeve when needed. Patients will also wear the adjustable compression sleeve in alternation with a standard compression sleeve over a six month maintenance phase.
Study NCT04884035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 by mouth at the assigned dose starting on Day 1 for 14 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
Study NCT04884035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion or 1400 mg (SC) subcutaneous (from Cycle 2) of a 21-day treatment cycle for up to a total of 6 cycles
Study NCT04884035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
Study NCT04922333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing placebo tablets
Study NCT05988515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech-Language Pathologist-led Speech Motor Chaining
Description: Sessions begin with Pre-practice to elicit the /r/ sound. During Structured Practice, the same utterance is practiced several times in a row (with systematic increases in difficulty based on performance). Our web-based software manipulates the principles of motor learning, including feedback prompts for the clinician, the complexity of the utterance, and the variability in the practice trial; the software will analyze the clinician's rating to increase the difficulty of practice when the child is more accurate. Randomized Practice will also be guided by the software and includes all linguistic levels that were produced correctly during Structured Practice, with items presented in random order. A trained speech-language pathologist is involved in all practice trials to provide feedback throughout the session.
Study NCT05988515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence-led Speech Motor Chaining (CHAINING-AI)
Description: Sessions include Structured Practice and Randomized Practice using our web-based software with an Artificial Intelligence clinician to address the /r/ sound. Within a practice session, participants speak into a microphone, and the audio file is sent to a server to be analyzed by a classifier, which returns a binary accurate/inaccurate rating of productions in a fashion similar to SLP judgment. Our web-based software manipulates the principles of motor learning, including feedback prompts, the complexity of the utterance, and the variability in the practice trial. The software will analyze the child's accuracy as determined by the classifier to increase the difficulty of practice when the child is more accurate.
Study NCT05935527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POLAT-001
Description: Subjects will be randomized to receive three injections per under eyebag, either 1 mg/mL or 2 mg/mL and 120 microliter volume, at each of three treatment visits.
Study NCT05935527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized to receive three injections of 120 microliters total of Normal Saline per under eyebag at each of three treatment visits.
Study NCT05378464 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cell (DC1) Vaccine
Description: Participants will receive a DC1 vaccine injection at 1.0-2.0 x 10\^7 cells, either to groin lymph notes or to tumor if accessible once a week for 3 weeks on days 1, 8 and 15. Participants will receive DC1 vaccine boosters every 3 weeks x 3.
Study NCT04884035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m2 IV infusion on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
Study NCT04884035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) IV intravenous on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
Study NCT04884035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
Study NCT04884035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99282
Description: CC-99282 by mouth at the assigned dose starting on Day 1 for 7 consecutive days of the 21-day treatment cycle for 6 cycles of treatment.
Study NCT04884035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Polatuzumab vedotin 1.8 mg/kg on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
Study NCT04884035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
Study NCT06428916 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tucking position during endotracheal suctioning
Description: , the staff nurse will perform the endotracheal suctioning while the researcher will carried out the intervention
Study NCT06227676 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cramp Bites by Aunt Flo's Kitchen
Description: Participants who are randomly assigned this snack are instructed to eat one serving each day, starting 2 days before their next onset of menstruation, and extending 3 days into their menstrual cycle. They are instructed to eat their assigned snack each time they experience menstrual cramps, whether spasmodic or congestive.
Study NCT06227676 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cramp Bites by Aunt Flo's Kitchen
Description: Participants who are randomly assigned this snack are instructed to eat one serving each day, starting 2 days before their next onset of menstruation, and extending 3 days into their menstrual cycle. They are instructed to eat their assigned snack each time they experience menstrual cramps, whether spasmodic or congestive.
Study NCT06311968 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiotherapy
Description: Patients who received R0 resection will receive 45GyE per 18 fractions proton irradiation. Patients who received R1 resection will receive 50GyE per 20 fractions proton irradiation. Patients with thymus cancer should receive combined platinum based chemotherapy (including etoposide combined with cisplatin / carboplatin / loplatin / nedaplatin, paclitaxel combined with cisplatin / carboplatin / loplatin / nedaplatin, Docetaxel combined with cisplatin / carboplatin / loplatin / nedaplatin) for at least 4 cycles.
Study NCT06311968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined platinum based chemotherapy
Description: combined platinum based chemotherapy
Study NCT05660551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Demostration
Description: This group will be demonstrated on a model after the theoretical training. The maneuvers used in the management of shoulder dystocia will be shown to the students on the model, respectively.
Study NCT05660551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telesimulation
Description: After the theoretical training for this group, telesimulation will be applied. A scenario will be created for the telesimulation experience and a video will be shot with this scenario. These videos will be watched by the students in groups of 4 on Microsoft Teams and a case discussion will be made through this scenario.
Study NCT05660551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kahoot Game
Description: Kahoot, a game-based program, will be applied to this group one week after the theoretical training. The game will be organized according to the learning objectives and achievements related to shoulder dystocia.
Study NCT04541550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMP-001 Low Dose
Description: AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
Study NCT04541550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMP-001 Medium Dose
Description: AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.
Study NCT04541550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMP-001 High Dose
Description: AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.